PRESENTATION
Q2 2025 — Presentation
Q2 2025PDF · 15 pages213 KB
Elevance Health 2Q 2025 Earnings Presentation July 17, 2025 -- 1 of 15 -- 22 The Value We Deliver We advance whole health through innovative solutions that integrate physical, behavioral, and social care to achieve our purpose of improving the health of humanity For Consumers Simple, Affordable, and Accessible Health Care 1. Simplifying healthcare through enhanced digital capabilities that personalize member experiences 2. Affordability at the core of our innovative plan designs 3. Accessibility through advocacy and data driven solutions that elevate whole health 1. Differentiated clinical partnerships built on shared expertise and coordinated care 2. Advanced clinical collaboration and value-based care 3. Aligned business partner through digital tools that enhance information exchange and reduce administrative burden For Care Providers Deepen Clinical and Business Partnerships -- 2 of 15 -- 3 Key Highlights • Elevance Health second quarter results reflect disciplined execution • Operating revenue of $49.4B grew more than 14% • Medical loss ratio of 88.9% increased 260 bps • Adjusted diluted EPS1 of $8.84 • Returned $2.0B to shareholders year-to-date through dividends and share repurchases 2Q 2025 Results 1 • Revising full year adjusted diluted EPS1 guidance to approximately $30.00 • 2025 benefit expense ratio to be approximately 90.0%, reflecting the ongoing and industry-wide impact of elevated cost trends in our ACA and Medicaid businesses • Updating operating cash flow guidance to approximately $6.0 billion, primarily reflecting our revised earnings outlook and unfavorable working capital impacts 2025 Outlook 2 • Elevance Health is executing a clear strategy to strengthen performance and drive our enterprise flywheel • Accelerating our capabilities through advanced digital and AI tools to personalize the healthcare journey • Actively streamlining prior authorizations, with over half of electronic requests now processed in real time • Investing in advanced analytics to identify and reduce wasteful spending and enhance system integrity • Ensuring long-term, sustainable growth through disciplined pricing, growth in Carelon, and expansion of value-based care models to deliver value for our members and shareholders over time Strategic Focus Areas 3 1. See “GAAP Reconciliation” on slides 12 and 13 herein. -- 3 of 15 -- 44 Key Highlights • Elevance Health second quarter results reflect the diversity and resilience of our business as we navigate an elevated trend environment • Operating revenue of $49.4B grew 14.3%, attributable to higher premium yields in Health Benefits, recently closed acquisitions, and increased Medicare Advantage membership (partially offset by Medicaid attrition) • Medical loss ratio of 88.9% primarily reflects slower Medicaid rate alignment and higher ACA cost trends • Adjusted operating expense ratio was 10.0%, an improvement of 140 bps, reflecting expense leverage and our ongoing commitment to disciplined cost management • Operating cash flow of $2.1B included an improved working capital position 2Q 2025 Results Change (%/bps) 2Q 2024 2Q 2025 Elevance Health 14.3% $43.2B $49.4B Operating Revenue 1 260 bps 86.3% 88.9% Medical Loss Ratio (140) bps 11.4% 10.0% Adjusted Operating Expense Ratio1,2 (14.2%) $2.9B $2.5B Adjusted Operating Gain1,2 (170) bps 6.7% 5.0% Adjusted Operating Margin 1,2 (4.3%) $508M $486M Net Investment Income (14.2%) $10.30 $8.84 Adjusted Diluted EPS 2 $1.6B $0.4B $2.1B Operating Cash Flow 1. See “Basis of Presentation” on slide 11 herein. 2. See “GAAP Reconciliation” on slides 12 and 13 herein. -- 4 of 15 -- 55 Key Highlights • Health Benefits second quarter results reflect accelerated revenue growth; membership mix shifts and elevated utilization weighed on operating gain • Operating revenue grew 11.9% year over year, driven by higher premium yields, recently closed acquisitions, and growth in Medicare Advantage membership (partially offset by Medicaid attrition) • Adjusted operating margin of 3.8% declined by 200 bps, due to higher Medicaid and ACA cost trend, partly offset by operating efficiencies • Membership of 45.6M reflects Medicaid redeterminations, offset by targeted growth and higher retention rates in Medicare Advantage, and increases in Commercial risk-based membership Change (%/bps) 2Q 2024 2Q 2025 Health Benefits 11.9% $37.2B $41.6B Operating Revenue 1 (27.8%) $2.2B $1.6B Adjusted Operating Gain1,2 (200) bps 5.8% 3.8% Adjusted Operating Margin 1,2 (0.3%) 45.8M 45.6M Membership 1. See “Basis of Presentation” on slide 11 herein. 2. See “Reportable Segment Highlight Details” on slide 14 herein. Health Benefits 2Q 2025 Results -- 5 of 15 -- 66 Key Highlights • Strong revenue growth fueled by the scaling of innovative risk-based capabilities and integration of acquisitions, underscoring our strategic focus on advancing our enterprise flywheel for growth • CarelonRx operating revenue includes growth in adjusted scripts and contribution from recent acquisitions in specialty pharmacy services; adjusted operating margin impacted by ongoing initiatives to accelerate growth as we expand up market • Carelon Services operating revenue expansion of over 60% reflects the addition of CareBridge and the scaling of risk-based solutions; adjusted operating margin reflects improved Carelon Health performance, slightly offset by the dilutive effect of CareBridge 2Q 2025 Results Change (%/bps) 2Q 2024 2Q 2025 Carelon 35.8% $13.3B $18.1B Operating Revenue 1 25.0% $0.7B $0.9B Adjusted Operating Gain1,2 (40) bps 5.6% 5.2% Adjusted Operating Margin 1,2 6.5% 78.2M 83.3M Adjusted Scripts (4.9%) 102.3M 97.3M Consumers Served 1. See “Basis of Presentation” on slide 11 herein. 2. See “Reportable Segment Highlight Details” on slide 14 herein. Health Services -- 6 of 15 -- 77 Flywheel Supports Our Long-Term Growth Algorithm Health Benefits Optimize the Core Invest in Growth Accelerate Targeting at least 12% average annual growth in Adjusted Diluted Earnings Per Share Approximately 46M medical members balanced across commercial, Medicaid and Medicare, leveraging the assets and capabilities of Carelon to accelerate growth As an integrated portfolio of whole health solutions serving approximately 100M consumers, Carelon connects care across physical, behavioral, social, home health, and pharmacy needs to bend the cost curve, enhance consumer experiences, and deliver whole health, affordably Health Services -- 7 of 15 -- 88 Adjusted Operating Gain – High Single Digit to Low Double Digit CAGR1 Long-Term Growth Algorithm Revenue Growth High Single Digit CAGR1 Adjusted Operating Margin Expanding to 6.5% - 7.0% Capital Deployment Approximately 4% Contribution to Adjusted Diluted EPS CAGR 1 Health Benefits Mid to High Single Digit CAGR Driven by membership growth, cost trend, geographic expansion, and growth in specialized populations Carelon Services High Teens to Low Twenties CAGR Driven by risk-based revenue growth including M&A CarelonRx Low Double Digit CAGR Driven by script volumes and drug mix Transforming our business processes by leveraging new technologies across operations Commitment to operating efficiency and optimizing core businesses Effective medical management Underwriting discipline Share Repurchases Organic Reinvestment Programmatic M&A targeting integrated solutions that strengthen health plan competitiveness + + Targeting at least 12% average annual growth in Adjusted Diluted EPS 1. CAGR = Compound Annual Growth Rate Target. -- 8 of 15 -- 99 Committed to Strong Growth Over the Long-Term M&A/ Organic Reinvestment 50% Share Repurchase 30% Dividends 20% 5.3% 6.5% – 7.0% 2024 Target $175B High Single Digit CAGR1 2024 Target Elevance Health 5.8% Mid to High Single Digit 2024 Target $54B Mid Teens CAGR1 2024 Target Carelon 2 4.2% 5.5% – 6.5% 2024 Target $150B Mid to High Single Digit CAGR1 2024 Target Health Benefits Capital Allocation Targeting at least 12% average annual growth in Adjusted Diluted EPS Adjusted 3 Operating Margin Revenue (in billions) 1. CAGR = Compound Annual Growth Rate Target. 2. The CAGR target for revenue and the operating margin target for Carelon includes: (i) a low double-digit revenue CAGR and 6.0% – 6.5% operating margin target for CarelonRx, and (ii) a high teens to low twenties revenue CAGR and mid to high single digit operating margin for Carelon Services. 3. See “GAAP Reconciliation” on slides 12 and 13 herein. -- 9 of 15 -- 10 Forward-Looking Statements This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations. -- 10 of 15 -- 11 Non-GAAP Measures and Basis of Presentation This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP are available on Slides 12-13 of this document. Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in understanding and analyzing Elevance Health’s operating and financial results. -- 11 of 15 -- 12 12 Elevance Health GAAP Reconciliation — Shareholders’ Net Income and Shareholders’ Earnings Per Diluted Share Six Months Ended Jun 30 Three Months Ended Jun 30 Change 2024 2025 Change 2024 2025 (In millions, except per share data) (13.6)% $4,546 $3,926 (24.2)% $2,300 $1,743 Shareholders' net income Add / (Subtract): 278 302 162 147 Amortization of other intangible assets 246 595 85 131 Net losses on financial instruments 116 133 64 53 Transaction and integration related costs1 11 15 9 10 Litigation and settlement expenses1 119 — 59 — Business dispositions and related items 2 — — 4 — Business optimization charges 1 (240) — (240) — Gain on sale of business (134) (255) (38) (87) Tax impact of non-GAAP adjustments 396 790 105 254 Net adjustment items (4.6)% $4,942 $4,716 (17.0)% $2,405 $1,997 Adjusted shareholders' net income (10.9)% $19.44 $17.33 (21.6)% $9.85 $7.72 Shareholders’ earnings per diluted share Add / (Subtract): 1.19 1.33 0.69 0.65 Amortization of other intangible assets 1.05 2.63 0.36 0.58 Net losses on financial instruments 0.50 0.59 0.27 0.23 Transaction and integration related costs1 0.05 0.07 0.04 0.04 Litigation and settlement expenses1 0.51 — 0.25 — Business dispositions and related items 2 — — 0.02 — Business optimization charges 1 (1.03) — (1.03) — Gain on sale of business (0.57) (1.13) (0.16) (0.39) Tax impact of non-GAAP adjustments 1.40 3.49 0.45 1.12 Net adjustment items (1.5)% $21.14 $20.82 (14.2)% $10.30 $8.84 Adjusted shareholders’ earnings per diluted share Six Months Ended Jun 30 Three Months Ended Jun 30 Change 2024 2025 Change 2024 2025 (In millions) (14.1)% $5,925 $5,089 (23.2)% $2,986 $2,292 Income before income tax expense (973) (1,076) (508) (486) Net investment income (240) — (240) — Gain on sale of business 246 595 85 131 Net losses on financial instruments 545 685 280 341 Interest expense 278 302 162 147 Amortization of other intangible assets (3.2)% $5,781 $5,595 (12.3)% $2,765 $2,425 Reportable segments operating gain 1. Adjustment item resides in the Corporate & Other reportable segment. 2. Adjustment item resides in the Health Benefits and Carelon Services reportable segments. 3. Totals may not foot due to rounding. -- 12 of 15 -- 13 13 Elevance Health GAAP Reconciliation — Operating Gain, Operating Expense Ratio, and 2025 Outlook Six Months Ended Jun 30 Three Months Ended Jun 30 Change 2024 2025 Change 2024 2025 (In millions) 3.5% $9,952 $10,297 (1.4)% $5,066 $4,997 Operating expense Add / (Subtract): (116) (133) (64) (53) Transaction and integration related costs1 (11) (15) (9) (10) Litigation and settlement expenses1 (119) — (59) — Business dispositions and related items 2 — — (4) — Business optimization charges 1 (246) (148) (136) (63) Net adjustment items 4.6% $9,706 $10,149 0.1% $4,930 $4,934 Adjusted operating expense 14.8% $85,496 $98,186 14.3% $43,223 $49,421 Operating revenue (110) bp 116% 10.5% (160) bp 11.7% 10.1% Operating expense ratio (110) Bp 11.4% 10.3% (140) bp 11.4% 10.0% Adjusted operating expense ratio Six Months Ended Jun 30 Three Months Ended Jun 30 Change 2024 2025 Change 2024 2025 (In millions) (3.2)% $5,781 $5,595 (12.3)% $2,765 $2,425 Reportable segments operating gain Add / (Subtract): 116 133 64 53 Transaction and integration related costs1 11 15 9 10 Litigation and settlement expenses1 119 — 59 — Business dispositions and related items 2 — — 4 — Business optimization charges 1 246 148 136 63 Net adjustment Items (4.7)% $6,027 $5,743 (14.2)% $2,901 $2,488 Reportable segments adjusted operating gain Full Year 2025 Outlook Approximately $24.10 Shareholders’ earnings per diluted share Add / (Subtract): $3.28 Net losses on financial instruments3 $2.98 Amortization of other intangible assets3 $1.35 Transaction and integration related costs1, 3 $0.10 Litigation and settlement expenses1, 3 Approximately ($1.81) Tax impact of non-GAAP adjustments3 $5.90 Net adjustment items Approximately $30.00 Adjusted shareholders’ earnings per diluted share 1. Adjustment item resides in the Corporate & Other reportable segment. 2. Adjustment item resides in the Health Benefits and Carelon Services reportable segments. 3. Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount. -- 13 of 15 -- 14 14 Elevance Health Reportable Segment Highlight Details Six Months Ended Jun 30 Three Months Ended Jun 30 Change 2024 2025 Change 2024 2025 (In millions, Unaudited) Operating Revenue 11.6% $74,417 $83,013 11.9% $37,159 $41,582 Health Benefits 23.3% 16,841 20,759 21.3% 8,774 10,643 CarelonRx 63.4% 8,554 13,977 63.7% 4,545 7,441 Carelon Services 59.4% 249 397 90.2% 122 232 Corporate & Other NM 5 (14,565) (19,960) NM 5 (7,377) (10,477) Eliminations 14.8% $85,496 $98,186 14.3% $43,223 $49,421 Total Operating Revenue1 Operating Gain (Loss) (14.8)% $4,432 $3,777 (27.3)% $2,145 $1,560 Health Benefits 2 11.6% 1,020 1,138 7.8% 497 536 CarelonRx 78.9% 498 891 92.3% 208 400 Carelon Services2 NM 5 (169) (211) NM 5 (85) (71) Corporate & Other 2,3 (3.2)% $5,781 $5,595 (12.3)% $2,765 $2,425 Total Operating Gain1,4 Operating Margin (150) bp 6.0% 4.5% (200) bp 5.8% 3.8% Health Benefits (60) bp 6.1% 5.5% (70) Bp 5.7% 5.0% CarelonRx 60 bp 5.8% 6.4% 80 bp 4.6% 5.4% Carelon Services (110) bp 6.8% 5.7% (150) Bp 6.4% 4.9% Total Operating Margin1 1. See “Basis of Presentation” on slide 14 herein. 2. Operating Gain for the three and six months ended June 30, 2024, included $59 and $119 million, respectively, of 2024 business dispositions and related items; including $44 and $88 million, respectively, for the Carelon Services segment; and $15 and $31 million, respectively, for the Health Benefits segment. Operating Gain for the three and six months ended June 30, 2024, included $64 and $116 million, respectively, of transaction and integration related costs, $9 and $11 million, respectively, of litigation and settlement expenses, and $4 and $0 million, respectively, of business optimization charges, all of which reside in the Corporate & Other reportable segment. 3. Operating Gain for the three and six months ended June 30, 2025, included $53 and $133 million, respectively, of transaction and integration related costs and $10 and $15 million, respectively, of litigation and settlement expenses, which reside in the Corporate & Other reportable segment. 4. Operating Gain for the three and six months ended June 30, 2025, and June 30, 2024, included items excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on slides 13 and 14 herein. 5. "NM" = calculation not meaningful. Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Employee Program businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as well as corporate expenses not allocated to our other reportable segments). -- 14 of 15 -- -- 15 of 15 --